Milnacipran Rivopharm (Milnacipran Hydrochloride)

Milnacipran blocks the reuptake of the neurotransmitters serotonin and norepinephrine at neuronal synapses. By preventing their reabsorption, it raises their concentrations in the central nervous system, correcting the neurochemical imbalances associated with depression and enhancing mood and cognition.

The exact dose of Milnacipran Rivopharm is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical guidelines and patient-specific factors.

Safety data for milnacipran in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Milnacipran is an SNRI, offering dual inhibition of serotonin and norepinephrine reuptake, whereas many other antidepressants (e.g., SSRIs) target only serotonin. This broader mechanism can be advantageous for patients who do not respond adequately to serotonin‑selective agents, but individual response varies.

Milnacipran Rivopharm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency.

Milnacipran Rivopharm is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include hypertension, tachycardia, serotonin syndrome, suicidal thoughts or behaviors (especially early in treatment), and rare cases of severe liver injury. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Milnacipran is contraindicated in patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have a known hypersensitivity to milnacipran or any of its excipients. Caution is also advised for individuals with uncontrolled hypertension, severe hepatic impairment, or a history of serotonin syndrome.